key: cord-0982993-1kg83znr
authors: Nizet, Adrien; Foguenne, Jacques; Gothot, André; Tassin, Françoise; Keutgens, Aurore
title: Laboratory divergences in concurrent diagnosis of acute myeloid leukemia relapse and COVID‐19: A case report
date: 2021-04-21
journal: Int J Lab Hematol
DOI: 10.1111/ijlh.13553
sha: 4fda63ea8b47fb3ec662ec3c5184f1ac3ba18f78
doc_id: 982993
cord_uid: 1kg83znr

nan

In this case, the patient was treated by Remdesivir for five days as recommended by the National Institute Health (NIH) USA guidelines and AML therapy was delayed until a negative SARS-CoV-2 PCR. Four weeks later, BM aspirate smear revealed a fibrous and hypocellular marrow with elevated lymphocytosis (40.3%), few plasma cells (2.3%) and an increased blastosis (27%). Flow cytometry immunophenotypic analysis identified 6.5% myeloblasts with weak CD45, HLA-DR, CD34, CD117, strong CD33, and weak CD11c. Peripheral blood smear showed 3% blasts proving the evolution of AML and its blood infiltration. Finally, the patient was treated by a second allogeneic SCT two months after the diagnosis of the AML relapse.

In conclusion, simultaneous diagnosis of COVID-19 and hematological malignancies represent an important and a critical challenge for clinicians and clinical laboratory specialists to provide to the patient a right diagnosis, an appropriate care, and an adequate treatment.

None.

Morphological anomalies of circulating blood cells in COVID-19

Peripheral blood morphologic findings in patients with COVID-19

Plasmacytoid lymphocytes in SARS-CoV-2 infection (Covid-19)

The challenge of COVID-19 and hematopoietic cell transplantation. EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy

Concurrent diagnosis of acute myeloid leukemia and COVID-19: a management challenge

Treating leukemia in the time of COVID-19

Impact of Covid-19 on the treatment of acute myeloid leukemia

COVID-19 outcomes in patients with hematologic disease